First Wave BioPharma Announces FDA Clearance of IND Application for Phase 2a PASSPORT Trial of FW-ICI-AC as Treatment for Immune Checkpoint Inhibitor-Associated Colitis

NEXT STORY
Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital
PREV STORY
Zai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK Trial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6

author_avatar
NASDAQ Market News

Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereology

MENLO PARK, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty ...

author_avatar
NASDAQ Market News

Sanofi et Regeneron annoncent que la FDA a accordé la désignation de « Découverte capitale » au cemiplimab (REGN2810) dans le traitement du carcinome épidermoïde cutané au stade avancé

 Sanofi et Regeneron annoncent que la FDA a accordé la désignation de « Découverte ...

author_avatar
NASDAQ Market News